___

• 1. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267–76.
• 2. Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep 2010;10(3):224–31.
• 3. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95(5):735–45.
• 4. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999;45(4):923–9.
• 5. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85(9):704–10.
• 6. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79(7):1381–93.
• 7. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77(2):373–80.
• 8. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991;12(1):42–9.
• 9. Morimura T, Kitz K, Stein H, Budka H. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neurooncol 1991;10(1):1–11.
• 10.Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P. The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours. Acta Neurochir (Wien) 1987;89(3-4):117–21.
• 11.Zuber P, Hamou MF, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988;22(2):364–8.
• 12.Raghavan R, Steart PV, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol 1990;16(2):123–33.
• 13.Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns BJ, et al. Prognostic significance of Ki67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 1994;34(4):674–8.
• 14.Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66(2):373–85.
• 15.Torp SH, Helseth E, Dalen A, Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 1992;117(3-4):182–6.
• 16.Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 1994;74(7):1921–6.
• 17.Kindblom LG, Ahldén M, Meis-Kindblom JM, Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 1995;427(1):19–26.
• 18.Cunningham JM, Kimmel DW, Scheithauer BW, O’Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997;86(1):121–30.
• 19. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15(4):1294–301.
• 20.Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20(8):2076– 84.
• 21. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97–109.
• 22.Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66(2):373–85.
• 23. Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D, et al. Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys 2002;52(4):996–1001.
• 24.Willett CG, Warland G, Cheek R, Coen J, Efird J, Shellito PC, et al. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. J Clin Oncol 1994;12(4):679–82.
• 25. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78(4):703–11.
• 26.Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267(5203):1456–62.
• 27. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74(6):957–67.
• 28. Little JB. Differential response of rapidly and slowly proliferating human cells to X irradiation. Radiology 1969;93(2):307–13.
• 29.McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997;56(7):798–805.
• 30.Dirven CM, Koudstaal J, Mooij JJ, Molenaar WM. The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuroradiological follow-up. J Neurooncol 1998;37(1):9–16.
• 31.Hilton DA, Love S, Barber R, Ellison D, Sandeman DR. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 1998;42(4):724–9.
• 32.Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, et al. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000;58(2):108–16.
• 33.Johannessen AL, Torp SH. The clinical value of Ki-67/ MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006;12(3):143–7.